Highly sensitive in vitro cytokine release assay incorporating high-density preculture

Highly sensitive in vitro cytokine release assay incorporating high-density preculture

Immunostimulatory effects of monoclonal antibodies (mAb) through binding to Fcγ receptors (FcγR) on immune cells are a likely cause of cytokine release syndrome. However, it is difficult to detect the potential risk of FcγR-dependent cytokine release associated with mAb in the current standard cytok...

Full description

Bibliographic Details
Main Authors:	Shiho Ito, Kyoko Miwa, Chiharu Hattori, Tetsuo Aida, Yoshimi Tsuchiya, Kazuhiko Mori
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Series:	Journal of Immunotoxicology
Subjects:	cytokine release syndrome high-density preculture fcγr cytokine release assay therapeutic monoclonal antibody peripheral blood mononuclear cell
Online Access:	http://dx.doi.org/10.1080/1547691X.2021.1984617

Similar Items

Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format
by: Khiyam Hussain, et al.
Published: (2019-03-01)

An adaptable in vitro cytokine release assay (CRA): Susceptibility to cytokine storm in COVID-19 as a model
by: Masih Alam, et al.
Published: (2022-01-01)

Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment
by: Maria Cosenza, et al.
Published: (2021-07-01)

Influence of polyamines of bacterial origin on the production of key cytokines in the culture of human mononuclear leukocytes
by: A. P. Godovalov, et al.
Published: (2022-04-01)

Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report
by: Antonina E. Shchekina, et al.
Published: (2021-07-01)

Immunomodulating Phytochemicals: An Insight Into Their Potential Use in Cytokine Storm Situations
by: Abdusalam Abdullah Alarabei, et al.
Published: (2024-03-01)

The effect of statin administration on IL-6 and IL-1b expression in peripheral blood mononuclear cells of a hypertensive patient with SARS-CoV-2 spike protein stimulation
by: Andrianto Andrianto, et al.
Published: (2022-08-01)

Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review
by: Khalid Eljaaly, et al.
Published: (2021-06-01)

Cytokine Release Syndrome: An Overview on its Features and Management
by: Shailza Shreshtha, et al.
Published: (2019-03-01)

Significant difference in Th1/Th2 paradigm induced by tuberculosis-specific antigens between IGRA-positive and IGRA-negative patients
by: Qiang Li, et al.
Published: (2022-08-01)

A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?
by: Monique Aucoin, et al.
Published: (2021-09-01)

Oral Lactobacillus strains reduce cytotoxicity and cytokine release from peripheral blood mononuclear cells exposed to Aggregatibacter actinomycetemcomitans subtypes in vitro
by: Nuntiya Pahumunto, et al.
Published: (2020-09-01)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
by: Tom van Kraaij, et al.
Published: (2020-04-01)

Rituximab induced cytokine release syndrome in an MS patient: A case report
by: Masoud Etemadifar, et al.
Published: (2021-07-01)

Cytokine release syndrome
by: Alexander Shimabukuro-Vornhagen, et al.
Published: (2018-06-01)

High Ferritin in a Critically ill COVID-19 Patient: The Calm before Cytokine Storm
by: Safa Saki, et al.
Published: (2020-07-01)

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
by: Riegler LL, et al.
Published: (2019-02-01)

IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
by: Huihui Zhang, et al.
Published: (2022-01-01)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
by: David Porter, et al.
Published: (2018-03-01)

Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19
by: I Jerlin Michelle, et al.
Published: (2021-01-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL
by: Harbani K. Malik-Chaudhry, et al.
Published: (2021-01-01)

Nanoparticle-Mediated Delivery of Flavonoids: Impact on Proinflammatory Cytokine Production: A Systematic Review
by: Jazmín Cristina Stevens Barrón, et al.
Published: (2023-07-01)

Cytokine Release Syndrome: Current Perspectives
by: Murthy H, et al.
Published: (2019-10-01)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
by: Antonio Mastroianni, et al.
Published: (2020-07-01)

Nicotine Modulates the Release of Inflammatory Cytokines and Expression of TLR2, TLR4 of Cord Blood Mononuclear Cells
by: Laya Takbiri Osgoei, et al.
Published: (2018-08-01)

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR‐mutated non‐small‐cell lung cancer: A case report
by: Meng Zhang, et al.
Published: (2022-05-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01)

The use of cytokines in the treatment of cornea inflammatory and dystrophic diseases (review)
by: M. S. Denisko, et al.
Published: (2020-08-01)

The Many Faces of JAKs and STATs Within the COVID-19 Storm
by: Alice H. Grant, et al.
Published: (2021-07-01)

Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2
by: Wang LG, et al.
Published: (2022-05-01)

Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy
by: Kyoko Yoshihara, et al.
Published: (2022-01-01)

Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
by: Cohen S, et al.
Published: (2019-01-01)

CD32 Ligation Promotes the Activation of CD4+ T Cells
by: María Pía Holgado, et al.
Published: (2018-11-01)

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
by: Gilles Thibault, et al.
Published: (2021-06-01)

Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions
by: Robert Root-Bernstein
Published: (2021-02-01)

Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease
by: Daiji Takamoto, et al.
Published: (2022-09-01)

INFLUENCE OF ALPHA-1-ACID GLYCOPROTEIN UPON PRODUCTION OF CYTOKINES BY PERIPHERAL BLOOD MONONUCLEARS
by: М. V. Osikov, et al.
Published: (2014-07-01)

Hydroxyapatite-Coated SPIONs and Their Influence on Cytokine Release
by: Bernhard Friedrich, et al.
Published: (2021-04-01)